In "Changes in Bone Mineral Density after Antiretroviral Initiation with Tenofovir Disoproxil Fumarate-Emtricitabine plus Atazanavir-Ritonavir, Darunavir-Ritonavir, or Raltegravir [J Infect Dis. 2015 Oct 15; 212(8):1241-9.] by Brown et al. there are three errors noted by the authors:
Lines 176-180 Corrected sentence should read:
The following monocyte cell phenotypes were characterized and expressed as percentages: classical phenotype (CD14+CD16-), intermediate phenotype (CD14+CD16+), non-classical phenotype (CD14dimCD16+). CD4+ and CD8+ T cells with activated (HLA-DR+CD38+), senescent (CD28-CD57+) or senescent and exhausted (CD28-CD57+PD1+) phenotypes were assessed.
Lines 279-282 Corrected sentence should read:
Associations of monocyte subpopulations (% MNC: CD14+CD16+, % MNC: CD14dimCD16+) with bone loss at either the lumbar spine or the total hip or were also not consistently detected (data not shown). % MNC: CD14+CD16+ 9.7 (5.9, 13.8) 9.7 (5.0, 13.1) 9.0 (5.7, 11.7)
Values represent median (Q1,Q3) or percent; † W: white; B: black; H:hispanic; remaining represents other *includes androgen, anticonvulsants, proton pump inhibitors, corticosteroids, estrogens, SSRIs
